Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up ...

The six were among 40 finalists nationwide in the Regeneron Science Talent Search, the country's most prestigious science ...

Emma Wen, a senior at Great Neck North High School, is researching more effective ways to fight pancreatic cancer.

Through the generous support of Regeneron, four times a year River Journal publishes the on-site report of a high school science student from the River Towns who is paired with a Regeneron […] ...

Regeneron Science Talent Search alumni have gone on to win ... engineering, environmental science, medicine and health genomics, materials science, mathematics, neuroscience, computer science, animal ...